Find a trial
As with everything in 2020, pulmonary fibrosis clinical trials and PACT activities have been majorly impacted by COVID-19. Trial investigators and sites are doing all they can to negotiate the changing conditions and keep recruiting trial participants. Please continue to check our website for trial updates, we hope to be able to reopen trial enquiries soon. To stay up to date, become a member.Become a member
PACT partnership with HealthMatch to help patients access clinical trials.
Finding and accessing clinical trials can be difficult for Pulmonary Fibrosis patients. PACT has partnered with HealthMatch to make this process easier and more efficient. Use the link below to find out more about matching for current and future Pulmonary Fibrosis clinical trials and create a profile.Find out more
Deciding to be part of a clinical trial is a very personal decision. People eligible to participate in a clinical trial are limited to a group with very specific characteristics. Please see below clinical trials that are currently recruiting in Australasia. If you are interested in any of the listed trials please register your interest by clicking here. You will then be able to enter your contact details which will then be forwarded to the PACT coordinator. If you are interested in participating in a trial your information may be passed onto a local clinical trials coordinator.
|Isabela 1&2||A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Two Doses of GLPG1690 in Addition to Local Standard of Care for Minimum 52 Weeks in Subjects With ldiopathic Pulmonary Fibrosis||Recruiting|
|PFOX||PFOX: Pulmonary Fibrosis Ambulatory Oxygen Trial||Recruiting|
|HIIT||High intensity interval training in fibrotic interstitial lung disease||Recruiting|
|GRIPF||Genetic research in Idiopathic Pulmonary Fibrosis (GRIPF)||Recruiting|
|HHF-ILD||Handheld fan for breathlessness in interstitial lung disease||Recruiting|
Trials in Follow Up
|ATLAS||A Randomized Open-Label, Phase 1b Study of the Safety of Pirfenidone Solution for Inhalation (AP01) in Patients with Idiopathic Pulmonary Fibrosis||Closed to recruitment||Trial Summary
Study Id: ACTRN12618001838202
|Trail1||A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease (RAILD)||Closed to recruitment||Trial Summary Study ID: NCT02808871|
|COLDICE||Cryobiopsy versus Open Lung biopsy in the Diagnosis of Interstitial lung disease allianCE||Study completed|
|SPIRIT||A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis (IPF)||Study completed|
|SCENIC||Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF): SCENIC Trial||Discontinued
The SCENIC study was terminated due to the impact of COVID-19. The study was being conducted across 11 countries and while the impact was minimal in Australasia this was not the case in the other regions.